HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.
about
The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic InitiativeDrug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United StatesUpdate on Advances in Research on Idiosyncratic Drug-Induced Liver InjuryEvolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response.Idiosyncratic adverse drug reactions: current conceptsLiver safety assessment in special populations (hepatitis B, C, and oncology trials)Pharmacogenomics of adverse drug reactionsPathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinibThe Possible Mechanism of Idiosyncratic Lapatinib-Induced Liver Injury in Patients Carrying Human Leukocyte Antigen-DRB1*07:01Recursive Random Lasso (RRLasso) for Identifying Anti-Cancer Drug TargetsDrug-induced liver injury: recent advances in diagnosis and risk assessment.Human leucocyte antigen-adverse drug reaction associations: from a perspective of ethnicity.Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management.Hepatotoxicity of targeted therapy for cancer.HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.Pharmacogenomics of off-target adverse drug reactions.A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data.Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinomaGenotyping for severe drug hypersensitivity.Drug-Induced Liver Injury: Cascade of Events Leading to Cell Death, Apoptosis or NecrosisHepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis.Assay of lapatinib in murine models of cigarette smoke carcinogenesis.In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteersPharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.Ongoing challenges in pharmacovigilance.Causality assessment for suspected DILI during clinical phases of drug developmentSaliva sampling in global clinical studies: the impact of low sampling volume on performance of DNA in downstream genotyping experimentsT cell-mediated hypersensitivity reactions to drugsSusceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles.Drug-induced liver injury: the dawn of biomarkers?Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study.Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials DatabaseComprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01.Testing for drug hypersensitivity syndromes.Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs.Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?Liver injury induced by anticancer chemotherapy and radiation therapy.Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.
P2860
Q26764776-05688712-B644-44C2-B8BB-C097A052CF53Q26767296-39CFC405-6871-40D6-AD1E-FF016C433489Q26779078-419D9DA6-7292-415B-9E9F-EE773F35FD4FQ26800980-0CA02F3F-8FA6-49C7-B1F7-150782BD9499Q26824391-54256943-E8A0-4672-AD8B-39349FA25AB3Q27008502-AAC582F7-A0DC-44F4-BA8D-C299A50FBCBAQ27015820-7620F0ED-558B-4380-A378-814BCB4C04E2Q27690772-D5646577-3BB3-4461-B53B-62E3AC9A5E42Q27692095-FAF894FE-4FDB-43BF-828E-33F52D27F58CQ28080497-2C864A3A-F600-4B13-976C-6D619DFF110BQ28548544-77D24030-2B62-4627-A0F8-CA17887036CCQ28550739-F61C16D7-F01A-47DD-9FB7-6B3137FA5383Q30235089-A8B31F0D-8F83-4DFD-8E5D-E2D1055B94B1Q30238992-89D4ED0D-639B-4006-ABF3-CEF41CB5CF7FQ30241050-D0A6A434-AF7C-4B3A-96A0-DB2E409BF481Q30250288-4B863E83-3169-4C95-B933-DFB682BFE676Q30371340-305A182A-116B-4D47-9634-BE2EF349CD40Q30400366-BA856D37-1E66-4A8C-93CB-B7AF442FBD4EQ30585177-FF31605F-BEF6-4D46-ABB2-E472AD1106AFQ31108636-6574B3AC-530A-4CDF-B6CA-43FE9D389D59Q33582530-DB7EFAEE-BED9-420B-B472-FDA221A4F991Q33755165-1D78F599-0422-411C-BBB3-CEE0D3ECD183Q33794548-791A98CF-B078-4BDD-86EC-C0FCB98B6450Q34260243-4F370109-2E79-492D-880B-33A52E9F8579Q34316771-150DE760-68CD-44C0-AEDB-5DCAA434C177Q34342305-4CAEFDFA-D0DE-44F6-AA87-4448F0FE8374Q34417013-609BD020-491F-444A-BD9E-061CC9CFA900Q34417032-4629F4D2-E00A-47E9-9C29-9F4D7718F70CQ34768758-78C9DA1E-8C64-4061-A6BE-493C1F360E8EQ34971993-641152A9-5826-461B-A2CD-AE00E0A9ADC2Q35085772-369C329E-4841-492C-8A65-E22E6966AE96Q35210890-54002830-A163-48BB-B565-A045EF0360AFQ35863499-1AE2ADA5-D82F-4A61-AF71-B383E846C09AQ36171663-FC227747-9EF9-418C-9EF1-5724CB0F7604Q36762374-F08C26C7-3159-4FA3-B419-D5FC8BD24748Q36766056-07888DF3-E98E-4F12-8DE2-5C20EDF1E5F0Q36796350-05EBB1D0-3389-4840-8492-22E6DAF8BE32Q36811351-85F33C92-3E62-4C32-8A9F-25D703DE3034Q37067634-C4D68FDA-33C7-48E9-92F2-A2572513ADE1Q37121662-3949ACEF-80AD-4326-8236-ABA93D08EC54
P2860
HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
HLA-DQA1*02:01 is a major risk ...... n with advanced breast cancer.
@en
HLA-DQA1*02:01 is a major risk ...... n with advanced breast cancer.
@nl
type
label
HLA-DQA1*02:01 is a major risk ...... n with advanced breast cancer.
@en
HLA-DQA1*02:01 is a major risk ...... n with advanced breast cancer.
@nl
prefLabel
HLA-DQA1*02:01 is a major risk ...... n with advanced breast cancer.
@en
HLA-DQA1*02:01 is a major risk ...... n with advanced breast cancer.
@nl
P2093
P356
P1476
HLA-DQA1*02:01 is a major risk ...... n with advanced breast cancer.
@en
P2093
Alaknanda J Preston
Charles J Cox
Colin F Spraggs
Karen S King
Laura R Budde
Linda P Briley
Lon R Cardon
Steven H Stein
Vincent E Mooser
P304
P356
10.1200/JCO.2010.31.3197
P407
P577
2011-01-18T00:00:00Z